静脉免疫球蛋白市场基于(关键地区、市场参与者、规模和份额)- 到 2031 年的预测

  • Report Code : TIPRE00004079
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 210
Buy Now

2021年静脉注射免疫球蛋白市场价值为112.0654亿美元,到2028年可能达到186.7255亿美元;预计 2022 年至 2028 年复合年增长率为 7.6%。

免疫球蛋白是人体免疫系统自然产生的抗体,有助于抵抗感染和疾病。免疫球蛋白缺乏需要外部给予免疫球蛋白,称为免疫球蛋白替代疗法(IgRT)。 IgRT 可以静脉注射和皮下注射。根据适应症和严重程度选择静脉注射免疫球蛋白(IVIg)和皮下注射免疫球蛋白(SCIg)。 IVIg 由人血浆制成。它含有抗体,用于治疗越来越多的免疫、血液和神经系统疾病。

战略见解

静脉注射免疫球蛋白市场分为类型、应用、分销渠道、最终用户和地理位置。按地域划分,市场大致分为北美、欧洲、亚太地区、中东和中东地区。非洲、南美和非洲中美洲。该报告提供了对市场的见解和深入分析,强调市场趋势、市场动态以及全球领先市场参与者的竞争分析等参数。

< h3>静脉免疫球蛋白市场利润丰厚的区域

市场洞察

免疫缺陷疾病患病率的上升和老年人口的增加正在推动静脉免疫球蛋白市场的发展。

根据美国国家过敏和传染病研究所 (NIAID) 的数据,超过 200 种不同类型的原发性免疫缺陷疾病 (PIDD) 影响着美国约 500,000 人。罕见的遗传疾病可能是慢性的、弱的且昂贵的。免疫性血小板减少症 (ITP) 是一种自身免疫性出血性疾病,其特征是血小板水平异常低;一种称为血小板减少症的情况。据罕见疾病组织称,全球每年记录约 20 万例 ITP 病例。此外,根据联合国人口司的《2019年世界人口展望》,亚洲和欧洲国家的65岁及以上人口数量居世界之首。日本以 28% 位居榜首,其次是意大利,为 23%。此外,芬兰、葡萄牙和希腊位列老年人口低于22%的前五名国家之列。许多接受 IVIG 治疗的患者年龄都在 60 岁以上。随着年龄的增长,产生 T 细胞对抗疾病的能力显着降低。因此,老年人的身体很容易发生多种感染和疾病,这增加了对涉及使用IVIg的免疫疗法的需求。因此,全球范围内免疫缺陷疾病的增加和老年人口的增加正在提振静脉注射免疫球蛋白市场。

基于类型的见解

根据类型,静脉注射免疫球蛋白市场分为 IgG、IgM、IgA、IgE 和 IgD。 IgG 型免疫球蛋白细分市场在 2021 年占据最大的市场份额。然而,由于 IgG 广泛应用于治疗多种疾病,预计手持细分市场在预测期内复合年增长率最高。

静脉注射免疫球蛋白市场(按类型) 2021年和2028年

基于应用的见解

根据应用,静脉注射免疫球蛋白市场分为低丙种球蛋白血症、慢性炎症性脱髓鞘性多发性神经病、免疫缺陷病、重症肌无力、多灶性运动神经病、特发性血小板减少性紫癜、炎症性肌病、特异性抗体缺乏症、吉兰-巴利综合征等。 2021年,免疫缺陷疾病领域占据了最大的市场份额。此外,由于免疫缺陷疾病患病率不断上升,以及 FDA 越来越多地批准用于治疗免疫缺陷的 IVIg 产品,预计该细分市场的需求将从 2022 年到 2028 年以最快的复合年增长率增长。

分销渠道-基于洞察

根据分销渠道,静脉注射免疫球蛋白市场分为医院药房、零售药房等。 2021年,医院药房领域占据最大的市场份额。此外,由于零售药店的扩张以及消费者行为向提供高质量药品和药品的有组织零售药店的转变,预计 2022 年至 2028 年零售药房领域的需求将以最快的复合年增长率增长。< /p>

基于最终用户的见解

根据最终用户,静脉注射免疫球蛋白市场分为医院、专科诊所等。 2021年,医院细分市场占据最大市场份额。此外,由于专科诊所在向患者提供快速、准确的 IgRT 方面取得了进步,预计从 2022 年到 2028 年,专科诊所的需求将以最快的复合年增长率增长。

产品等有机发展批准是全球静脉注射免疫球蛋白市场参与者广泛采用的策略。下面列出了近期的一些关键市场动态:

  • 2022 年 3 月,ADMA Biologics, Inc. 宣布美国食品和药物管理局 (FDA) 批准延长该药物的有效期。其 ASCENIV 和 BIVIGAM 免疫球蛋白 (“IG”) 药品在 2-8°C 下储存的有效期为 24 至 36 个月。有效期延长适用于目前商业供应链中的所有现有 ASCENIV 和 BIVIGAM 批次,以及未来所有西林瓶尺寸、生产规模以及内部和外部灌装成品药品的 ASCENIV 和 BIVIGAM 生产。
  • 2021 年 6 月,Octapharma 宣布,octagam 10% 是一种人血浆来源的静脉注射免疫球蛋白 (IVIg),最近已在欧盟 (EU) 获得批准,用于成人皮肌炎的免疫调节疗法。继欧盟批准后,octagam 10% 于 2021 年 5 月 11 日在德国获得国家批准,预计其他欧洲成员国也将很快获得批准。
  • 2021 年 4 月,ADMA Biologics, Inc. 宣布美国食品和药物管理局 (“FDA”) 批准了该公司扩大的生产工艺,能够对 4,400 升血浆池进行分级和纯化,用于生产静脉免疫球蛋白 (“IVIG”)。
  • 2020 年 2 月,CSL Behring 宣布美国食品和药物管理局 (FDA) 授予 Privigen(静脉注射免疫球蛋白(人),10% 液体)孤儿药资格,作为治疗系统性硬化症 (SSc) 的研究疗法。< /li>

市场参与者的此类发展正在推动静脉注射免疫球蛋白市场。

静脉注射免疫球蛋白 -市场细分

全球静脉注射免疫球蛋白市场按类型、应用、分销渠道、最终用户和地理位置进行细分。根据类型,市场分为 IgG、IgM、IgA、IgE 和 IgD。按应用划分,市场分为低丙种球蛋白血症、慢性炎症性脱髓鞘性多发性神经病、免疫缺陷疾病、重症肌无力、多灶性运动神经病、特发性血小板减少性紫癜、炎症性肌病、特异性抗体缺乏症、格林-巴利综合征等。根据分销渠道,市场分为医院药房、零售药房等。按最终用户划分,市场分为医院、专科诊所等。按地域划分,市场分为北美、欧洲、亚太地区、中东和北美。非洲、南美和非洲中美洲。

公司简介

  • 武田药品工业株式会社
  • Grifols, SA
  • 辉瑞公司
  • < li>ADMA Biologics Inc.
  • 生物制品实验室有限公司
  • 上海莱士
  • Octapharma AG
  • Kedrion SpA
  • < li>CSL Behring(CSL 有限公司)
  • Prothya Biosolutions BV
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are intravenous immunoglobulins?

Immunoglobulins are the antibodies produced naturally by the body’s immune system, which help fight infection and disease. The deficiency of immunoglobulin requires the external administration of immunoglobulin and known as immunoglobulin replacement therapy (IgRT). IgRT can be given intravenously and subcutaneously. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are selected based on the indication and severity. IVIg is manufactured from human plasma. It contains antibodies and is used in the treatment of a growing number of immunologic, hematologic and neurologic illnesses.

Which segment led the intravenous immunoglobulin market?

The IgG segment under type segment, held the largest share in 2021.

Who are the key players in the intravenous immunoglobulin market?

The intravenous immunoglobulin market majorly consists of the players such as Takeda Pharmaceutical Company Limited; Grifols, S.A.; Pfizer Inc.; ADMA Biologics Inc.; Bio Products Laboratory Ltd.; Shanghai RAAS; Octapharma AG; Kedrion S.p.A; CSL Behring (CSL Limited); and Prothya Biosolutions B.V.

Which region is fastest growing?

Based on geography, the APAC region is accounted for highest CAGR in intravenous immunoglobulin market during the forecast period.

The List of Companies - Intravenous Immunoglobulin Market

  1. Takeda Pharmaceutical Company Limited
  2. Grifols, S.A.
  3. Pfizer Inc.
  4. ADMA Biologics Inc.
  5. Bio Products Laboratory Ltd.
  6. Shanghai RAAS
  7. Octapharma AG
  8. Kedrion S.p.A
  9. CSL Behring (CSL Limited)
  10. Prothya Biosolutions B.V.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports